iCAD, Inc. (ICAD)

Market Cap	39.82M
Revenue (ttm)	17.32M
Net Income (ttm)	-4.85M
Shares Out	26.37M
EPS (ttm)	-0.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	78,052
Open	1.480
Previous Close	1.460
Day's Range	1.450 - 1.540
52-Week Range	1.050 - 3.970
Beta	1.36
Analysts	Strong Buy
Price Target	5.00 (+231.13%)
Earnings Date	May 15, 2024

About ICAD

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Dec 3, 1986
• Employees: 67
• Stock Exchange: NASDAQ
• Ticker Symbol: ICAD

Financial Performance

In 2023, iCAD, Inc.'s revenue was $17.32 million, a decrease of -12.54% compared to the previous year's $19.80 million. Losses were -$4.85 million, -64.51% less than in 2022.

Analyst Forecast

According to one analyst, the rating for ICAD stock is "Strong Buy" and the 12-month stock price forecast is $5.0.

Price Target

$5.0

(231.13% upside)

Analyst Consensus: Strong Buy